Fractyl Health Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
73
- Stock Symbol
-
GUTS
- Share Price
-
$0.83
- (As of Friday Closing)
Fractyl Health General Information
Description
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
Contact Information
Website
www.fractyl.comCorporate Office
- 3 Van de Graaff Drive
- Suite 200
- Burlington, MA 01803
- United States
Corporate Office
- 3 Van de Graaff Drive
- Suite 200
- Burlington, MA 01803
- United States
Fractyl Health Stock Performance
As of 20-Nov-2026, Fractyl Health’s stock price is $0.83. Its current market cap is $10.9M with 13.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.83 | $0.96 | $0.78 - $29.34 | $10.9M | 13.3M | 502K | -$3.11 |
Fractyl Health Financials Summary
As of 30-Sep-2026, Fractyl Health has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 100,254 | 286,025 | 77,351 | |
| Revenue | 0 | 0 | 93 | 120 |
| EBITDA | (75,049) | (141,365) | (72,163) | (78,065) |
| Net Income | (74,197) | (140,954) | (68,694) | (77,091) |
| Total Assets | 65,925 | 121,402 | 108,077 | 76,212 |
| Total Debt | 59,533 | 61,646 | 62,500 | 86,391 |
Fractyl Health Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Fractyl Health Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Fractyl Health Comparisons
Industry
Financing
Details
Fractyl Health Competitors (22)
One of Fractyl Health’s 22 competitors is Diamyd Medical, a Corporation company based in Stockholm, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Diamyd Medical | Corporation | Stockholm, Sweden | ||||
| Carmot Therapeutics | Formerly VC-backed | Berkeley, CA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| MannKind | Formerly VC-backed | Danbury, CT | ||||
| XBiotech | Corporation | Austin, TX |
Fractyl Health Patents
Fractyl Health Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260263640-A1 | Gene therapy compositions, methods, and systems for weight loss and maintenance | Pending | 10-Mar-2025 | ||
| WO-2026192937-A1 | Systems, methods, and compositions for weight loss and maintenance | Pending | 10-Mar-2025 | ||
| AU-2025206052-A1 | Glp-1 gene therapies for metabolic disorders | Pending | 05-Jan-2024 | ||
| EP-4837039-A1 | Glp-1 gene therapies for metabolic disorders | Pending | 05-Jan-2024 | ||
| WO-2025147630-A1 | Glp-1 gene therapies for metabolic disorders | Inactive | 05-Jan-2024 | C12N15/86 |
Fractyl Health Signals
Fractyl Health ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.85 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Fractyl Health FAQs
-
When was Fractyl Health founded?
Fractyl Health was founded in 2010.
-
Where is Fractyl Health headquartered?
Fractyl Health is headquartered in Burlington, MA.
-
What is the size of Fractyl Health?
Fractyl Health has 73 total employees.
-
What industry is Fractyl Health in?
Fractyl Health’s primary industry is Drug Discovery.
-
Is Fractyl Health a private or public company?
Fractyl Health is a Public company.
-
What is Fractyl Health’s stock symbol?
The ticker symbol for Fractyl Health is GUTS.
-
What is the current stock price of Fractyl Health?
As of 20-Nov-2026 the stock price of Fractyl Health is $0.83.
-
What is the current market cap of Fractyl Health?
The current market capitalization of Fractyl Health is $10.9M.
-
Who are Fractyl Health’s competitors?
Diamyd Medical, Carmot Therapeutics, Dicerna Pharmaceuticals, MannKind, and XBiotech are some of the 22 competitors of Fractyl Health.
-
What is Fractyl Health’s annual earnings per share (EPS)?
Fractyl Health’s EPS for 12 months was -$3.11.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process